However, with the antibody-based (Tastuzumab/Herceptin) therapeutic approach as an adjunctive treatment for Her-2 positive breast cancer patients, the prognosis of this patient group has significantly improved [12, 13]. The gene discussed is ERBB2; the disease is breast carcinoma.